Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carla Territo

Retina Specialist Florissant, MO Medical Doctor

NPI 1851403190 CMS profile 355929

1224 Graham Rd, Suite 3011, Florissant, MO 63031

Open in the dashboard

General payments

$20,520

224 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$33,417

4 holdings reported · through program year 2025

Through program year 2025, Carla Territo of Florissant, MO is reported in the CMS Open Payments database as having received $20,520 across 224 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $33,417 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,322 19
2024 General $3,643 42
2023 General $2,315 40
2022 General $8,342 41
2021 General $1,925 28
2020 General $881 17
2019 General $2,092 37
2022 Ownership $8,333 1
2021 Ownership $8,333 1
2020 Ownership $8,375 1
2019 Ownership $8,375 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carla Territo
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Carla Territo were reported at $1,322. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Carla Territo Retina Specialist median Middle half National median
2019 $2,092 $410 $157–$1,517 $163
2020 $881 $168 $65–$778 $114
2021 $1,925 $258 $101–$1,161 $132
2022 $8,342 $418 $162–$1,488 $149
2023 $2,315 $476 $178–$1,312 $160
2024 $3,643 $520 $188–$1,372 $164
2025 $1,322 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. US Retina LLC $9,190 6 payments
  2. EyePoint Pharmaceuticals US, Inc. $2,116 4 payments
  3. Genentech USA, Inc. $1,504 48 payments
  4. Regeneron Healthcare Solutions, Inc. $1,058 35 payments
  5. Apellis Pharmaceuticals, Inc. $794 9 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $652 15 payments
  7. Bausch & Lomb Americas Inc. $582 8 payments
  8. Alimera Sciences, Inc. $579 19 payments
  9. Novartis Pharmaceuticals Corporation $519 14 payments
  10. Astellas Pharma US Inc $451 10 payments
  11. Other $3,076 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,480 217 payments
  2. Acquisitions $5,543 1 payment
  3. Current or prospective ownership or investment interest $3,647 5 payments
  4. Consulting Fee $1,850 1 payment
Products named General payments · program years 2019–2025
  1. EYP-1901 $1,975 2 payments
  2. VABYSMO $1,119 34 payments
  3. EYLEA $727 26 payments
  4. Syfovre $671 7 payments
  5. EYLEA HD $545 11 payments
  6. Izervay $451 10 payments
  7. ILUVIEN $335 12 payments
  8. PURIFIED CORTROPHIN GEL $325 2 payments
  9. OZURDEX $320 11 payments
  10. YUTIQ $309 11 payments
  11. Other $5,738 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

366

Median for Ophthalmology: 891

Drug cost

$11,917

Median for Ophthalmology: $68,233

Branded share of claims

22.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 98 $3,864
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 25 $3,406
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 46 $2,024
Ketorolac Tromethamine Generic 91 $1,572
Dorzolamide Hcl Generic 15 $297
Latanoprost Generic 52 $290
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 11 $185
Diclofenac Sodium Generic 12 $140
Timolol Maleate Generic 16 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$1,237,707

Of which drugs: $964,136

Medicare patients

587

Average age 77

Services billed

25,867

346 women, 241 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 37%
Chronic kidney disease 34%
Ischemic heart disease 31%
Atrial fibrillation 20%
Heart failure 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 85 18,361 $482,075
Injection, aflibercept, 1 mg J0178 Office 46 290 $187,000
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 15 870 $101,737

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech USA, Inc. $298
$298 — 18,361
Izervay
  • Astellas Pharma US Inc $277
$277 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $200
$200 — —
ILUVIEN
  • Alimera Sciences, Inc. $154
$154 — —
Syfovre
  • Apellis Pharmaceuticals, Inc. $146
$146 — 870

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record